Efficacy and Safety of First-line Immunotherapy-based Regimens for Patients with Extensive-stage Small Cell Lung Cancer: a Systematic Review and Network Meta-analysis

Overview

Journal Transl Lung Cancer Res

Date 2025 Feb 17

PMID 39958215

Authors

Wengang Zhang

Wencheng Zhao

Xinyu Zhang

Zhiyi Guo

Li Ye

Zhimin Chen

Kandi Xu

Lishu Zhao

Xinyue Liu

Yujin Liu

Hao Wang

Yayi He

Affiliations

Soon will be listed here.

Abstract

Background: Combination regimens of immunotherapy plus chemotherapy have been approved as the first-line and standard of care for extensive-stage small cell lung cancer (ES-SCLC). Novel regimens are continuously being explored, with the ETER701 study being the representative randomized controlled trial (RCT). ETER701 study has assessed the efficacy and safety of chemotherapy with or without anlotinib (multi-target angiogenesis inhibitor) + benmelstobart (programmed cell death ligand 1 inhibitor) (Anl/Ben/CT). There is no evidence-based medicine available proving that Anl/Ben/CT is the optimal regimen due to the lack of direct or indirect comparisons among varying immunotherapy-based regimens. In this study, we aimed to identify the optimal regimen to assist in clinical decision-making.

Methods: The eligible RCTs were identified by searching PubMed, Embase, Cochrane Library databases, and major international conferences. Then, the network meta-analysis was analyzed to compare the efficacy and safety among 15 first-line regimens in ES-SCLC. The Cochrane Risk of Bias Tool was used to assess the risk of bias in included studies.

Results: A total of 12 immunotherapy-related RCTs covering 15 interventions and 6,178 patients with ES-SCLC were included. Overall, most RCTs exhibited a low risk of bias across multiple domains. The results indicated that most immunotherapy-based regimens could significantly prolong progression-free survival (PFS) compared with chemotherapy alone, especially Anl/Ben/CT [hazard ratio (HR) 0.32, 95% confidence interval (CI): 0.25-0.40]. Similar results were observed regarding overall survival (OS), that is, most immunotherapy-related regimens dramatically reduced the risk of death in ES-SCLC, with Anl/Ben/CT being the most prominent (HR 0.61, 95% CI: 0.47-0.80). The Bayesian ranking probabilities showed that Anl/Ben/CT ranked first and serplulimab plus chemotherapy ranked second in both PFS and OS among 15 regimens. Regarding safety, Anl/Ben/CT ranked 3rd, and serplulimab plus chemotherapy ranked 7th.

Conclusions: Adding anlotinib and benmelstobart to chemotherapy significantly improved PFS and OS compared with chemotherapy alone or chemotherapy plus immunotherapy, with an acceptable safety profile in patients with ES-SCLC. In conclusion, Anl/Ben/CT could be a new, preferable first-line treatment option but further clinical studies are needed to validate its efficacy and safety.

References

Su Y, Luo B, Lu Y, Wang D, Yan J, Zheng J . Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma. Clin Cancer Res. 2021; 28(4):793-809. PMC: 9377760. DOI: 10.1158/1078-0432.CCR-21-2241. View

Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G . Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. JAMA. 2022; 328(12):1223-1232. PMC: 9516323. DOI: 10.1001/jama.2022.16464. View

Dias S, Welton N, Caldwell D, Ades A . Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010; 29(7-8):932-44. DOI: 10.1002/sim.3767. View

Owonikoko T, Park K, Govindan R, Ready N, Reck M, Peters S . Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. J Clin Oncol. 2021; 39(12):1349-1359. PMC: 8078251. DOI: 10.1200/JCO.20.02212. View

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Liu S, Reck M, Mansfield A, Mok T, Scherpereel A, Reinmuth N . Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021; 39(6):619-630. PMC: 8078320. DOI: 10.1200/JCO.20.01055. View

Yu L, Hu Y, Xu J, Qiao R, Zhong H, Han B . Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy. Int J Cancer. 2023; 153(3):635-643. DOI: 10.1002/ijc.34536. View

Cai Z, Gu X, Xie J, Cheng D, Chen J, Cheng J . Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in patients with extensive-stage small cell lung cancer: a multicenter retrospective analysis. Transl Lung Cancer Res. 2023; 12(10):1987-2000. PMC: 10654438. DOI: 10.21037/tlcr-23-294. View

Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G . Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022; 23(6):739-747. DOI: 10.1016/S1470-2045(22)00224-8. View

10.

Rossi A, Di Maio M, Chiodini P, Rudd R, Okamoto H, Skarlos D . Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012; 30(14):1692-8. DOI: 10.1200/JCO.2011.40.4905. View

11.

Byers L, Rudin C . Small cell lung cancer: where do we go from here?. Cancer. 2014; 121(5):664-72. PMC: 5497465. DOI: 10.1002/cncr.29098. View

12.

Oronsky B, Reid T, Oronsky A, Carter C . What's New in SCLC? A Review. Neoplasia. 2017; 19(10):842-847. PMC: 5596356. DOI: 10.1016/j.neo.2017.07.007. View

13.

Megyesfalvi Z, Gay C, Popper H, Pirker R, Ostoros G, Heeke S . Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023; 73(6):620-652. DOI: 10.3322/caac.21785. View

14.

Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R . Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer. Cancer Med. 2022; 12(5):5372-5383. PMC: 10028028. DOI: 10.1002/cam4.5360. View

15.

van Meerbeeck J, Fennell D, De Ruysscher D . Small-cell lung cancer. Lancet. 2011; 378(9804):1741-55. DOI: 10.1016/S0140-6736(11)60165-7. View

16.

Zhang T, Li W, Diwu D, Chen L, Chen X, Wang H . Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis. Front Immunol. 2023; 14:1197044. PMC: 10331819. DOI: 10.3389/fimmu.2023.1197044. View

17.

Socinski M, Smit E, Lorigan P, Konduri K, Reck M, Szczesna A . Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009; 27(28):4787-92. DOI: 10.1200/JCO.2009.23.1548. View

18.

Cheng Y, Chen J, Zhang W, Xie C, Hu Q, Zhou N . Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat Med. 2024; 30(10):2967-2976. PMC: 11485241. DOI: 10.1038/s41591-024-03132-1. View

19.

Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z . Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018; 11(1):120. PMC: 6146601. DOI: 10.1186/s13045-018-0664-7. View

20.

Salanti G, Ades A, Ioannidis J . Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2010; 64(2):163-71. DOI: 10.1016/j.jclinepi.2010.03.016. View